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Abstract
Background Newborn screening (NBS) in Germany currently includes 15 target disorders. Recent diagnostic improvements 
suggest an extension of the screening panel.
Methods Since August 2016, a prospective study evaluating 26 additional target disorders (25 metabolic disorders and 
vitamin  B12-deficiency) in addition to the German screening panel is performed at the Newborn Screening Center Heidel-
berg. First-tier results from tandem-MS screening are complemented by second-tier strategies for 15 of the additional target 
disorders. NBS results of seven patients diagnosed symptomatically with one of the additional target disorders by selective 
screening since August 2016 are retrospectively evaluated.
Results Over a 13-month period, 68,418 children participated in the study. Second-tier analyses were performed in 5.4% 
of samples. Only 59 (0.1%) of study participants had abnormal screening results for one of the additional target disorders. 
Target disorders from the study panel were confirmed in 12 children: 1 3-hydroxy-3-methylglutaryl coenzyme A (CoA)-lyase 
deficiency, 1 citrullinemia type I, 1 multiple acyl-CoA dehydrogenase-deficiency, 1 methylenetetrahydrofolate reductase-
deficiency, and 8 children with maternal vitamin  B12-deficiency. In addition, six of seven patients diagnosed symptomatically 
outside the study with one of the target disorders would have been identified by the study strategy in their NBS sample.
Conclusions Within 13 months, the study “Newborn Screening 2020” identified additional 12 children with treatable con-
ditions while only marginally increasing the recall rate by 0.1%. Maternal vitamin  B12-deficiency was the most frequent 
finding. Even more children could benefit from screening for the additional target disorders by extending the NBS panel for 
Germany and/or other countries.
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Introduction
Newborn screening (NBS) is a prerequisite for early diag-
nosis and successful treatment of many severe conditions 
presenting in the neonatal period or infancy. The German 
NBS panel currently includes 15 target disorders, including 
12 metabolic disorders, 2 endocrine disorders, and cystic 
fibrosis. Recent improvements in diagnostics and therapeu-
tics suggest an extension of the existing screening panel [1]. 
For example, there is conclusive evidence for the benefit of 
early identification by NBS and consecutive early treatment 
for patients with homocystinuria due to cystathionine ß-syn-
thase (CBS) deficiency, remethylation disorders, especially 
severe methylenetetrahydrofolate reductase (MTHFR) defi-
ciency, and some disorders of intracellular cobalamin (Cbl) 
metabolism [2–4]. In addition, for severe maternal vitamin 
 B12 deficiency, a clear benefit of early detection and treat-
ment is evident for both child and mother [5–7]. NBS for 
propionic aciduria and methylmalonic acidurias is recom-
mended in some countries, e.g., Austria, Spain, and the 
United States [8, 9], while others have decided not to include 
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these disorders in their screening panel [10, 11]. NBS for 
these disorders as well as for combined remethylation dis-
orders based on results for propionylcarnitine (C3) and its 
respective ratios with other acylcarnitines is, however, asso-
ciated with a high false-positive rate [10, 12]. Second-tier 
strategies have been proposed to reduce the false-positive 
rate [12–15].
Second-tier strategies are a promising tool for NBS. 
In this approach, by analysis of additional, more specific 
second-tier metabolites for the respective target disorder 
from the same first specimen in case of abnormal results 
for primary parameters, the false-positive rate in NBS may 
be significantly reduced. We previously evaluated and pre-
sented new strategies for NBS for classical homocystinu-
ria, remethylation disorders and vitamin  B12 deficiency in 
cohorts from Qatar and Germany [16, 17], and suggested 
a second-tier strategy for screening for these disorders in 
Germany using methionine (Met), ratio Met/phenylala-
nine (Met/Phe), C3 and ratio C3/acetylcarnitine (C3/C2) 
as first-tiers, and total homocysteine (tHcy) as second-tier 
if at least one of the first-tier parameters was out of range 
[16]. In August 2016, a study named “Newborn Screen-
ing (NBS) 2020” was started at the Newborn Screening 
Center, Heidelberg. In this project, an extension of the 
German NBS panel of 15 disorders (Table 1) by 26 addi-
tional conditions (25 metabolic disorders and vitamin  B12 
deficiency, Table 2) is evaluated including also remeth-
ylation disorders, propionic and methylmalonic acidurias, 
and vitamin  B12 deficiency, utilizing several second-tier 
strategies [18]. The objective of the study is to evaluate: 1) 
technical feasibility of NBS for these disorders in a popu-
lation-based NBS programme in Germany, and 2) the ben-
efit for detected patients based on whether patients were 
successfully identified presymptomatically. The rationale 
for now presenting findings of the first 13 months of this 
study is that awareness of these findings is important from 
a public health point of view. Providing proof for the feasi-
bility of the methods used in a population-based screening 
programme and of the benefit for patients identified will 
hopefully lead to timely inclusion of these additional dis-
orders into the NBS panel for Germany as part of regular 
health insurance. 
The target disorders were chosen according to: 1) the 
assumed feasibility of NBS using either first-tier param-
eters from tandem-MS screening only or additional second-
tier strategies from dried blood spots (DBS), and 2) the 
assumed benefit of early detection and early treatment. For 
some disorders, solely existing parameters from tandem-MS 
screening were used as first-tiers, which are so far already 
measured in all samples, but not evaluated in NBS accord-
ing to the German national screening panel, e.g., carnitine 
transporter deficiency, 3-hydroxy-3-methylglutaryl coen-
zyme A (HMG-CoA)-lyase deficiency, citrullinemia type I, 
argininosuccinate lyase deficiency, and multiple acyl-CoA 
dehydrogenase deficiency (MADD). For 15 of the target 
disorders, results from tandem-MS screening as first-tier 
results were complemented by second-tier testing from 
DBS for methylmalonic acid (MMA), 3-OH-propionic acid 
(3-OH-PA), methylcitric acid (MCA), and/or tHcy (com-
pare Table 2). In addition, screening for tyrosinemia type I 
was performed using succinylacetone from DBS as first-tier 
parameter. Disorders regarded as non-diseases such as e.g., 
short chain acyl-CoA dehydrogenase deficiency or 3-methyl-
crotonyl-CoA carboxylase deficiency or disorders without 
sufficient evidence for benefit of early treatment such as 
non-ketotic hyperglycinemia were not included in the study.
Methods
Newborn screening in the study NBS 2020
The national German NBS panel currently includes 15 dis-
orders (Table 1). Samples for NBS in Germany are to be 
taken between the 36th and 72nd hour of life onto NBS cards 
(Neonatal Screening Card; Whatman filter paper 903, GE 
Healthcare Europe GmbH, Freiburg, Germany) and dried for 
3–4 hours at room temperature. Samples are then transported 
to the Heidelberg NBS laboratory by mail. At this screen-
ing center, samples from about 130,000–140,000 newborns, 
mainly from southwest Germany, are screened every year. 
This equals about 17% of children born annually in Ger-
many. The population screened by this laboratory should be 













Maple syrup urine disease
Glutaric aciduria type I
Isovaleric aciduria
Medium-chain acyl-CoA dehydrogenase deficiency
Long-chain-3-OH-acyl-CoA-dehydrogenase deficiency
Very long-chain acyl-CoA-dehydrogenase deficiency
Carnitine palmitoyltransferase I deficiency
Carnitine palmitoyltransferase II deficiency
Carnitine acylcarnitine translocase deficiency
Cystic 
fibrosis
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representative for the rest of Germany without any known 
major differences in the incidence of certain target disorders 
of NBS [19] or differences concerning nutritional deficien-
cies. NBS including electrospray ionization tandem-MS 
(Micromass Ultima, Waters Xevo TQD, Waters, Milford, 
MA, USA) for determination of amino acids and acylcarni-
tines was performed in all samples as previously described 
[20]. In addition to the regular NBS panel, all senders (hos-
pitals, paediatricians, midwives, etc.) were asked to inform 
parents about the study NBS 2020 since August 2016. This 
study screens for 25 additional metabolic disorders and for 
vitamin  B12-deficiency (Table 2) from the same specimen as 
the regular NBS. By German legislation written informed 
consent of a least one legal guardian is required as a pre-
requisite for NBS. If parents decided to participate in the 
“NBS 2020” study, written informed consent for the study 
had to be sent with the sample to the Heidelberg Newborn 
Screening Center. The study was approved by the Institu-
tional Review Board of the University Hospital Heidelberg.
Metabolites already available from tandem-MS screening 
were used as primary markers for 25 of the target disorders 
in the study (Table 2). These parameters had already been 
measured for all samples before the study, but according 
to regulation results had to be blinded in medical valida-
tion as respective disorders are not targeted by the current 
German NBS panel. Screening for tyrosinemia type I was 
performed by measurement of succinylacetone from DBS as 
primary marker [21]. For 15 of the target disorders first-tier 
results from tandem-MS screening were complemented by 
second-tier testing from the same DBS for MMA, 3-OH-PA, 
MCA, and/or tHcy (compare Table 2). The algorithms to 
proceed to second-tier analysis were developed in analogy 
to the strategy previously proposed by us for samples from 
Germany based on a retrospective evaluation of confirmed 
patients with remethylation disorders and vitamin  B12 defi-
ciency [16]. In this strategy, second-tier measurements of 
tHcy from DBS are performed based on abnormal first-tier 
results for Met (< cut-off low) and Met/Phe ratio (< cut-
off low or > cut-off high). tHcy from DBS was analysed as 
described previously [22]. In addition to Hcy MMA, 3-OH-
PA, and MCA were analysed as second-tier parameters from 
the same DBS using a newly established method [23], based 
on abnormal first-tier results for C3 + ratio C3/C2 (> cut-
off), or ratio C3/C2 (> cut-off), or C3 above alarm limit. The 
respective first and second-tier parameters per target disorder 
are shown in Table 2. The cut-offs currently used in our 
study are shown for the relevant first-tier and all second-tier 
parameters per patient in Tables 3 and 4. 
Depending on the grade of pathology in the first DBS 
analysis, recommendations given are either to send a repeat 
sample for analysis of acylcarnitines and amino acids, tHcy, 
MMA, 3-OH-PA, and MCA in DBS, or to send also plasma 
and urine samples for additional analyses.
Diagnosis of vitamin  B12 deficiency in the child was 
established in cases with elevation of one or more functional 
markers of vitamin  B12 deficiency (MMA in plasma and/or 
urine, Hcy in plasma) in conformational analysis in the pres-
ence of vitamin  B12 serum levels below the norm or in the 
lower normal range. In addition, normalization of all func-
tional markers of vitamin  B12 deficiency and of vitamin  B12 
serum levels after supplementation had to be documented to 
establish this diagnosis. In all of these cases, work up of the 
Table 2  Additional target disorders and diagnostic algorithms in the study Newborn Screening 2020
CBS cystathionine ß-synthase, MTHFR methylenetetrahydrofolate reductase, Cbl cobalamin, Hcy homocysteine, HMG-CoA 3-hydroxy-3-meth-
ylglutaryl coenzyme A, MMA methylmalonic acid, MCA methylcitric acid
Disorders First tier Second tier
Tyrosinemia type I Succinylacetone None
Classical homocystinuria (CBS deficiency) Methionine/phenylalanine (high) Homocysteine
MTHFR deficiency, Cbl-D-Hcy, Cbl E-, G-defect Methionine (low), methionine/phenylalanine (low) Homocysteine
Cbl C-, D-, F-, J-defect, transcobalamin II deficiency Propionylcarnitine (C3), C3/acetylcarnitine (C2) MMA, MCA, homocysteine
Methylmalonic aciduria  (mut0,  mut−, Cbl A- and Cbl 
B-defect)
C3, C3/C2 MMA, MCA
Vitamin  B12 deficiency C3, C3/C2, methionine (low), methionine/phenylalanine 
(low)
MMA, MCA, homocysteine
Propionic aciduria C3, C3/C2 3-OH propionic acid, MCA
Urea cycle disorders, e.g., citrullinemia type I, arginino-
succinate lyase deficiency
Citrulline, argininosuccinate None
Multiple acyl-CoA dehydrogenase deficiency Multiple acylcarnitines (C4-C18) None
HMG-CoA lyase deficiency 3-hydroxyisovalerylcarnitine (C5-OH), methylglutaryl-
carnitine (C6-DC)
None
Carnitine transporter deficiency Free carnitine (C0) None
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mother’s vitamin  B12 status was recommended, including 
functional markers (MMA in plasma and/or urine, and Hcy 
in plasma). “Maternal vitamin  B12 deficiency” was stated 
if vitamin  B12 levels in the mother were below the normal 
range and/or functional markers of vitamin  B12 deficiency 
were elevated. This does not yet include any implications on 
the cause of the deficiency (nutritional, malabsorption, etc.). 
Dietary history in mothers was taken and in cases of “mater-
nal vitamin  B12 deficiency” which could not be explained 
by the mother’s dietary regimen, work-up by a specialist in 
internal medicine was recommended including evaluation of 
vitamin  B12 malabsorption. If results for vitamin  B12 were 
provided by an external laboratory in the unit pg/mL, results 
and reference ranges of the respective laboratory were con-
verted to pmol/L for better comparability and are presented 
in addition to the original result in the results section.
Measurement of MMA in urine and/or plasma for confor-
mational diagnostics in the metabolic laboratory in Heidel-
berg was performed using stable isotope-labelled D3-MMA 
as internal standard in analogy to [24].
Retrospective evaluation of NBS results 
and the strategy of NBS 2020 in patients identified 
by selective screening
During the course of the study, seven symptomatic patients 
with one of the target disorders of the study were diagnosed 
by selective metabolic investigation. Six of these patients 
were either born before the study had started (patients S2, 
S3, and S7) or did not participate in the study (patients S1, 
S5, and S6). Patient S4 participated in the study, but first-tier 
results in the first DBS did not fulfil criteria for second-tier 
analyses. The applied cut-offs of our study were retrospec-
tively evaluated in all these patients, in whom NBS results 
were available from our center. C3, C3/C2, Met, Met/Phe are 
being measured in all children from Germany screened by 
tandem-MS screening at our center before and outside the 
study, but according to regulation results have to be blinded 
in medical validation as respective disorders are not tar-
geted by the current German NBS panel. The results for 
these metabolites from tandem-MS screening are, however, 
available in the NBS database and were retrieved for this 
study. If the original NBS DBS was still available, second-
tier analyses (tHcy, MMA, 3-OH-PA, and MCA) were per-
formed retrospectively in the samples of these patients. If 
several dried blood spots had been measured in NBS for 
these patients (e.g., due to prematurity, etc.) the first sample 
taken after the age of 36 hours of life was evaluated. Retro-
spective evaluation of screening data of these patients has 
also been approved by the Institutional Review Board of the 
University Hospital Heidelberg.
Results
Newborn screening in the study NBS 2020
From 1st of August 2016 to 31st of August 2017, 68,418 
children participated in the study. Second-tier analyses were 
performed in 5.4% of these samples based on out-of-range 
first-tier results according to the decision criteria described 
above. After second-tier analysis, 59 (0.1%) of study par-
ticipants remained with abnormal screening results for one 
of the target disorders of the study, with need for a second 
DBS or additional work-up. Of these 59 cases, 33 were clas-
sified abnormal after use of a second-tier strategy, 26 were 
recalled for a target disorder without a second-tier strategy in 
place [9 carnitine transporter deficiency, 1 HMG-CoA-lyase 
deficiency, 2 citrullinemia type I, 1 MADD, 13 tyrosine-
mia type I (the high number of recalls for tyrosinemia type 
I being explained in the course of adaptation of a newly 
established cut-off for succinylacetone in DBS)]. In two of 
the 59 cases, the transfer of the final result of confirma-
tion is still pending (two cases with suspicion of vitamin 
 B12 deficiency or isolated remethylation disorder). A target 
disorder from the study panel was confirmed in altogether 
12 children. In four of these, an inherited metabolic disor-
der was confirmed: 1 HMG-CoA-lyase deficiency, 1 citrul-
linemia type I, 1 MADD, 1 MTHFR deficiency. In eight 
children and one additional sibling (twin) maternal vitamin 
 B12 deficiency was diagnosed. The screening results includ-
ing results of the second-tier analyses for the patients with 
maternal vitamin  B12 deficiency and isolated remethylation 
disorder (patients N1-N10) are shown in detail in Table 3. 
All patients were referred for further work-up to a metabolic 
center and all except one (MADD) were clinically asymp-
tomatic at time of diagnosis. The study participation rate at 
the end of the reported time period for the month of August 
2017 was 61.3%.
Patient N1 showed slightly elevated C3 and ratio C3/
C2, as well as slightly decreased Met in the first screen-
ing card. Second-tier analysis from this sample showed 
increased MMA, MCA and tHcy (for detailed results com-
pare Table 3). Work-up in patient N1 revealed elevated 
Hcy of 27.9 µmol/L in plasma, elevated methylmalonic 
acid in urine (280 mmol/mol Krea), and very low vitamin 
 B12 in serum (66 pg/mL; equivalent to 49 pmol/L). Also in 
the mother vitamin  B12 was low (185 pg/mL, N 191-663) 
(equivalent to 137 pmol/L, N 141-489), methylmalonic acid 
in plasma was slightly elevated, while Hcy in plasma was 
normal. The mother did not adhere to any restrictive (vegan/
vegetarian) diet during the pregnancy. The final diagnosis in 
the mother is pending, work-up has been planned including 
gastrointestinal malabsorption of vitamin  B12. The child was 
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treated with parenteral vitamin  B12, followed by oral supple-
mentation. This led to rapid normalization of all parameters 
(Hcy in plasma, methylmalonic acid, vitamin  B12). In addi-
tion, the mother has been supplemented with vitamin  B12 
parenterally.
Patient N2 showed decreased Met and ratio Met/Phe in 
the first screening card. Second-tier analysis from this sam-
ple showed increased tHcy. Work-up in patient N2 showed 
elevated Hcy in plasma of 36 µmol/L (N < 15), elevated 
methylmalonic acid in urine (quantification using stable 
isotope-labelled D3-MMA 101.8  mmol/mol creatinine, 
N < 10), and low normal vitamin  B12 in serum 258 pg/mL 
(N 211–911) (equivalent to 190 pmol/L, N 156–672). At 
the time of work-up in the child vitamin  B12 was also low 
in the mother (167 pmol/L, N 160–670), without any signs 
of functional vitamin  B12 deficiency (methylmalonic acid in 
urine and Hcy in plasma normal). The mother did not adhere 
to any restrictive diet during the pregnancy, but showed iron 
deficiency during pregnancy and was reported to have been 
a poor eater. The child was supplemented with vitamin  B12 
orally, which led to rapid normalization of all parameters 
(Hcy in plasma, methylmalonic acid in urine, and vitamin 
 B12). Therefore, the diagnosis of functional vitamin  B12 defi-
ciency in the child due to low maternal vitamin  B12 level 
was established.
Patient N3 showed elevated ratio Met/Phe with low 
normal Met in the first screening card. Second-tier analy-
sis from this sample showed increased tHcy. Work-up in 
patient N3 revealed elevated Hcy in plasma of 20 µmol/L 
(N < 15), elevated methylmalonic acid in urine (quantifica-
tion using stable isotope-labelled D3-MMA 38.8 mmol/
mol creatinine, N < 10), and low vitamin  B12 in serum 
(151 pmol/L, N 160–670). Vitamin  B12 was also low in 
the mother (159 pmol/L, N 160–670). The mother showed 
a slight elevation of Hcy in plasma (19 µmol/L, N < 15), 
and normal methylmalonic acid in urine. The mother did 
not adhere to any restrictive diet during pregnancy, but 
reported pronounced feeding difficulties in pregnancy due 
to massive heartburn. She showed severe iron deficiency 
during pregnancy which required supplementation. Patient 
N4, twin sibling to patient N3, was also diagnosed with 
vitamin  B12 deficiency in the course of selective work-
up due to the sibling’s (N3) abnormal NBS result. The 
child N4 himself had not fulfilled criteria for second-tier 
analysis in the first NBS sample (compare Table 3) and ret-
rospective analysis of the second-tier analytes in the origi-
nal NBS sample also revealed normal concentrations of 
tHcy and MMA. At the time of selective diagnostics aged 
22 days he showed slight elevation of markers for func-
tional vitamin  B12 deficiency [methylmalonic acid in urine 
(quantification using stable isotope-labelled D3-MMA) 
78.3 (N < 10); Hcy in plasma 18 µmol/L (N < 15); vitamin 
 B12 in plasma 144 pmol/L (N 160–670)] under feeding 
with infant formula. Both children (N3 and N4) were sup-
plemented with vitamin  B12 orally, which led to rapid nor-
malization of all parameters (Hcy, MMA, vitamin  B12). In 
both children also iron deficiency was detected and treated 
consecutively. The mother received counselling on food 
sources of vitamin  B12 and will be followed by a specialist 
in internal medicine.
Patient N5 showed elevated ratio C3/C2 in the first 
screening card, second-tier analysis from this card revealed 
slightly increased MMA, which was also confirmed in 
the second card. Work-up in this fully breast-fed child at 
age 3.5 weeks revealed slightly elevated Hcy in plasma of 
17 µmol/L (N < 15), elevated methylmalonic acid in urine 
(quantification using stable isotope-labelled D3-MMA 
53.8 mmol/mol creatinine, N < 10), and low vitamin  B12 in 
serum (79 pmol/L, N 160–670). Vitamin  B12 status in the 
mother is not known, as she refused further work-up for her-
self. The mother did not adhere to any restrictive diet during 
pregnancy. The child was supplemented with vitamin  B12 
orally, which led to rapid normalization of MMA in urine 
and vitamin  B12. Therefore, the diagnosis of maternal vita-
min  B12 deficiency as a cause of vitamin  B12 deficiency in 
this child was assumed.
Patient N6 showed decreased ratio Met/Phe in the first 
screening card. Second-tier analysis from this sample 
showed increased tHcy. Work-up at age 10 days in this 
fully breast-fed child revealed elevated Hcy in plasma of 
20.7 µmol/L (N < 15), elevated methylmalonic acid in urine 
(quantification using stable isotope-labelled D3-MMA 
39 mmol/mol creatinine, N < 10) and plasma (1.72 µmol/L, 
N 0.06–0.64), and low vitamin  B12 in serum (115 pmol/L, 
N 160–670). Vitamin  B12 was also low in the mother 
(131 pmol/L, N 160–670). The mother showed a slight 
elevation of Hcy in plasma (15.2 µmol/L, N < 15), and nor-
mal methylmalonic acid in urine and plasma. She did not 
adhere to any restrictive diet during pregnancy. The child 
was supplemented with vitamin  B12 orally, which led to 
rapid decrease of MMA in urine. For the mother work-up 
and treatment by a specialist in internal medicine has been 
recommended.
Patient N7 showed decreased Met and ratio Met/Phe in 
the first screening card. Second-tier analysis from this sam-
ple showed increased tHcy and MMA. This was confirmed 
in the second card, in which tHcy remained elevated and 
MMA had increased further. Work-up in patient N7 showed 
elevated Hcy in plasma of 21 µmol/L (N < 15), elevated 
methylmalonic acid in urine (171 mmol/mol creatinine, 
N < 18), and vitamin  B12 in serum in the low normal range 
with 374 pg/mL (N 210–910) (equivalent to 276 pmol/L, N 
155–672). The child was supplemented with vitamin  B12 
orally, which led to rapid normalization of Hcy in plasma 
and MMA in urine, while vitamin  B12 level had risen to the 
upper normal range. Therefore, the diagnosis of maternal 
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vitamin  B12 deficiency as a cause of functional vitamin  B12 
deficiency in this child was assumed. For the mother work-
up and treatment by a specialist in internal medicine has 
been recommended.
Patient N8 showed decreased Met and ratio Met/Phe in 
the first screening card. Second-tier analysis from this sam-
ple showed increased tHcy and MMA. This was confirmed 
in the second card, in which tHcy and MMA had increased 
further. Work-up in patient N8 showed elevated Hcy in 
plasma of 28 µmol/L (N < 15), elevated methylmalonic acid 
in urine (124 mmol/mol creatinine, N < 18). Vitamin  B12 in 
serum determined in the treating hospital was reported as 
decreased. The child was supplemented with vitamin  B12 
orally, which led to rapid normalization of Hcy in plasma 
and MMA in urine. For the mother work-up and treatment 
by a specialist in internal medicine has been recommended.
Patient N9 showed clearly decreased Met and ratio Met/
Phe in the first screening card. Second-tier analysis from this 
sample showed markedly increased tHcy. Work-up in patient 
N9 showed elevated Hcy in plasma of 135 µmol/L (N 5–12) 
and decreased Met in plasma of 6 µmol/L (N 10–40). Meth-
ylmalonic acid in urine and vitamin  B12 in serum were nor-
mal. Therefore, the diagnosis of an isolated remethylation 
disorder was established, final subspecification confirmed 
MTHFR deficiency. Treatment was started with betain, 
hydroxocobalamin and folinic acid.
Patient N10 showed decreased Met and ratio Met/Phe 
in the first screening card. Second-tier analysis from this 
sample showed increased tHcy. This was confirmed in the 
second card with elevated tHcy and now also elevated MCA. 
Work-up in patient N10 showed elevated Hcy in plasma of 
25 µmol/L (N < 15), elevated methylmalonic acid in urine 
(quantification using stable isotope-labelled D3-MMA 
23.8 mmol/mol creatinine, N < 10), and decreased vitamin 
 B12 in serum (104 pmol/L, N 160–670]. Vitamin  B12 was 
also low in the mother (141 pmol/L, N 160–670), with-
out any signs of functional vitamin  B12 deficiency (meth-
ylmalonic acid in urine and Hcy in plasma normal). The 
mother did not adhere to any restrictive diet during preg-
nancy. However, also in the father vitamin  B12 deficiency 
was known. For the mother work-up and treatment by a 
specialist in internal medicine has been recommended. The 
child was supplemented with vitamin  B12 orally, which led to 
rapid normalization of vitamin  B12 in serum, Hcy in plasma 
and MMA in urine.
Retrospective evaluation of NBS results 
and the strategy of NBS 2020 in patients identified 
by selective screening
During the course of the study, seven symptomatic patients 
with one of the target disorders of the study were diagnosed 
by selective metabolic investigation: two children with a 
combined remethylation disorder (patients S1 and S6), one 
child with mild propionic aciduria (patient S2), two children 
with vitamin  B12 deficiency (patients S3 and S4), and two 
children with methylmalonic aciduria (patients S5 and S7). 
The results of the tandem-MS analysis in the initial NBS 
sample and the sample taken at time of selective diagnostics, 
results of the (retrospective) second-tier analyses from DBS, 
as well as the time of storage before second-tier analysis are 
summarized in Table 4.
Patient S1 with combined remethylation disorder showed 
seizures on day 8 of life. The final subspecification of the 
combined remethylation disorder as confirmed by molecu-
lar genetic analysis is pending. This child would have been 
detected by our algorithm in the sample taken on day 8 of 
life, and also in the very first NBS sample, which was send to 
us from an external NBS center after consent of parents and 
was reanalysed at our laboratory 3 months after sampling.
Patient S2 with mild propionic aciduria was diagnosed in 
the course of a first metabolic decompensation with meta-
bolic acidosis, hypoglycemia, ketosis and hyperammonemia 
triggered by an infection aged 11 months. Patient S3 with 
vitamin  B12 deficiency was diagnosed aged 8 months due 
to failure to thrive. Patient S5 with methylmalonic aciduria 
showed metabolic decompensation on day 4 of life with 
hyperammonemia. At that time, the initial NBS sample, 
sent to an external NBS center, had not been analysed yet. 
Patient S6 with combined remethylation disorder (Cbl C 
defect) underwent selective diagnostics aged 3 weeks due 
to failure to thrive and muscular hypotonia. Patient S7 with 
methylmalonic aciduria showed metabolic decompensation 
aged 11 months. All these children would have been detected 
by our algorithms in the initial NBS sample.
Patient S4 was admitted aged 10 weeks with suspicion 
of seizures. Laboratory work-up revealed slight functional 
vitamin  B12 deficiency (vitamin  B12 126 pmol/L, N 160–670, 
methylmalonic acid in urine 137 mmol/mol creatinine, but 
normal Hcy in plasma with 13 µmol/L, N < 15). Vitamin  B12 
was at that time also low in the mother, who did not adhere 
to a restricted diet. The child was fully breastfed. The child 
had participated in the pilot project NBS 2020 but did not 
fulfil criteria for second-tier analysis in the NBS sample. 
Retrospective analysis from the initial NBS sample showed 
a normal tHcy concentration and only slightly increased 
methylmalonic acid in this sample.
Discussion
Within 13 months, the strategies used in a cohort of 68,418 
study participants in our project “Newborn Screening 2020” 
led to identification of additional 12 children with metabolic 
disorders or maternal vitamin  B12 deficiency while only 
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marginally increasing the recall rate by 0.1%. This means 
that in this cohort, about one in 5700 children was affected 
by one of the additional disorders, while about one in 1300 
children—equalling about 50 children in this cohort—is 
affected by one of the metabolic or endocrine disorders from 
the current German screening panel (compare Table 1) [19]. 
Eleven of 12 children identified so far with one of the target 
disorders from the study panel were diagnosed before the 
onset of clinical symptoms.
Maternal vitamin  B12 deficiency was the most frequent 
finding with about 1 in 8500 newborns in the screened popu-
lation. It is a particular strength of our pilot study that all 
mothers are referred for systematic assessment of vitamin 
 B12 status and evaluation of dietary history. None of the 
mothers who were evaluated adhered to a vegan or vegetar-
ian diet. Vitamin  B12 deficiency in these mothers was caused 
by nutritional problems during pregnancy or suspected unde-
tected dysfunctions of gastrointestinal absorption. While in 
all children in the NBS group, markers for functional vita-
min  B12 deficiency were elevated at time of conformational 
diagnosis, in their mothers markers of functional vitamin 
 B12 deficiency were only slightly abnormal or even normal 
despite low vitamin  B12 levels, which is in line with other 
reports [25].
As the current participation rate in our study is about 
60%, the true frequency of maternal vitamin  B12 defi-
ciency in the population screened by our laboratory—about 
130,000–140,000 newborns per year—may be even higher. 
Other programmes reported vitamin  B12 deficiency in chil-
dren mainly as a consequence of a maternal vegan or veg-
etarian diet [25–27]. The percentage of people following 
a vegan diet in Germany is estimated to be 0.1–1% of the 
population [28]. Based on the current participation rate, we 
cannot draw final conclusions at this point, whether this 
issue is not of relevance in the population screened by our 
laboratory, whether mothers with vegan/vegetarian diets are 
especially considerate during pregnancy concerning supple-
mentation of vitamin  B12, or if mothers with vegan/vegetar-
ian diets have so far been more reluctant to participate in 
the study.
A screening programme in Estonia revealed an incidence 
of vitamin  B12 deficiency as high as 1 in 2500 newborns 
[29]. A further study in Italy using C3 as first, and MMA as 
second-tier test in a NBS cohort of 35,000 children found 
vitamin  B12 deficiency in about 1 in 5000 newborns in a 
6-year period [25]. This study also evaluated vitamin  B12 
status in a cohort of unselected healthy females admitted 
to hospital for delivery and found low vitamin  B12 levels 
in about 48% of examined women [25]. It has to be consid-
ered in this context that serum Cbl levels decline throughout 
gestation [30, 31]. In accordance with this MMA and Hcy 
levels have been reported to increase by late pregnancy [32, 
33]. A Canadian study found that 10% of women are vitamin 
 B12 deficient in early pregnancy [34], and several consecu-
tive studies have confirmed similar findings or even higher 
frequencies for vitamin  B12 deficiency in pregnancy of up 
to 30% in different populations and ethnicities [31, 35–38]. 
This underscores the relevance of this condition for NBS 
programmes and stresses that also in caregivers of pregnant 
women awareness for  B12 deficiency should be increased.
Other programmes reported lower incidences of patients 
with vitamin  B12 deficiency detected by NBS [27, 39, 40]. 
Different strategies and cut-offs were used in different pro-
grammes [25, 27, 40, 41].
In addition, six of seven patients diagnosed symptomati-
cally with one of the target disorders outside the study would 
have been identified by our strategy in the first NBS sample. 
These patients were born just before the study had started 
or did not participate in the study. The combination of first 
tier cut-offs and second-tier strategies would have detected 
these patients. Most of these children could presumably have 
benefitted from early detection by NBS—especially those 
with late-onset symptoms and with vitamin  B12 deficiency 
[6, 16, 26]. For severe vitamin  B12 deficiency, several reports 
document that children diagnosed symptomatically may die 
or neurological deficits persist despite treatment [5]. This 
underscores the enormous benefit of early detection. For 
Cbl C deficiency, there is a clear benefit of early detection 
and treatment in patients with late-onset forms [2, 42]. How-
ever, it has to be noted, that although early treatment seems 
to have a beneficial effect on non-neurological symptoms 
and mortality in Cbl C deficiency, long-term neurological 
and ophthalmological symptoms may not be significantly 
influenced [43, 44]. A screening approach for Cbl C defi-
ciency based on low Met as secondary metabolite in cases 
with elevated C3 has been suggested by Weisfeld-Adams 
and colleagues [45]. However, in our collective, one of two 
patients with a combined remethylation disorder showed C3 
in the normal range in the first DBS sample.
Patient S5 with methylmalonic aciduria diagnosed symp-
tomatically showed a neonatal decompensation in the first 
days of life and could most probably not have been identified 
presymptomatically by NBS.
It has to be noted that in patient S3 with vitamin  B12 defi-
ciency, the first tier analyte Met/Phe was only slightly below 
our cut-off (low, P5) which triggers second-tier tHcy meas-
urement. Patient N4, twin sibling to patient N3, was diag-
nosed with maternal vitamin  B12 deficiency in the course of 
selective work-up due to the sibling’s abnormal NBS result. 
The child N4 himself did not fulfil criteria for second-tier 
analysis in the first NBS sample and also retrospective analy-
sis of the second-tier analytes in the original NBS sample 
revealed normal concentrations of tHcy and MMA. At the 
time of selective diagnostics aged 22 days, however, the 
child showed slight elevation of markers for functional vita-
min  B12 deficiency under feeding with infant formula. An 
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additional patient with slight vitamin  B12 deficiency (patient 
S4) diagnosed aged 10 weeks following laboratory work-up 
in the context of seizures had participated in the pilot project 
NBS 2020 and did not fulfil criteria for second-tier analysis 
in the NBS sample. As can be assumed from the normal 
tHcy concentration and the only slightly increased MMA 
in the retrospective analysis from the initial NBS sample, 
mild vitamin  B12 deficiency seems to have developed in the 
following months in this fully breastfed child. The clinical 
symptoms with seizures are, however, most probably unre-
lated to the mild vitamin  B12 deficiency. Of note, second-tier 
measurements in the initial NBS sample were performed 
retrospectively after 2.5 months of storage at 4 °C. For stor-
age of DBS at room temperature, an increase of MMA over 
time has been described [46], while MMA in DBS has been 
reported as stable for 8 weeks at 2–4 C° [47].
Different strategies in NBS for vitamin  B12 deficiency
The frequency of vitamin  B12 deficiency detected in NBS 
greatly depends on different strategies and cut-offs used in 
different programmes [25, 27, 40, 41]. Compared to our cur-
rent strategy, the study by Scolamieri and colleagues used a 
considerably lower cut-off for C3 (3.16 µmol/L, correspond-
ing to the 90th percentile of the laboratory) as criterion for 
second-tier analysis of MMA [25]. In the patients detected 
by NBS in Estonia, all C3 levels have been reported to have 
been > 4.31 µmol/L (percentile of the laboratory not stated) 
[29]. Concerning C3 our approach is rather conservative 
(cut-off between 99 and 99.5 P.), and also isolated elevation 
of C3/C2 in the presence of normal C3 leads to second-tier 
analysis of MMA in our strategy. Only one of our altogether 
11 patients with vitamin  B12 deficiency (NBS or selective 
screening) showed a C3 above our cut-off in the first NBS 
sample. This proportion rises only slightly to 4 of 11 patients 
even when applying the much lower cut-off for C3 used by 
Scolamiero and colleagues [25]. Also other studies have 
come to the conclusion, that C3 is an insensitive marker for 
vitamin  B12 deficiency [26].
In our patients with vitamin  B12 deficiency ratio Met/Phe 
was decreased in 6, elevated in 1 and normal in 4 patients 
in the initial NBS sample. It has previously been stated that 
MMA should be more sensitive for vitamin  B12 deficiency 
than Hcy, as the pathway of Met synthase is supposed to 
be more preserved than that of MMA-CoA mutase when 
vitamin  B12 stores are declining [25, 48]. In our collective 
MMA was elevated above the 99.9th percentile (cut-off for 
MMA and MCA in our study) in 6 of 11 children, and MCA 
in 3 of 11 children in the initial NBS sample. Therefore, the 
most sensitive marker in DBS seems to be Hcy, which was 
elevated in the first DBS in eight patients. It was initially 
normal in three children, including the two children who 
were not identified by our screening strategy in the first DBS 
and later on diagnosed with mild vitamin  B12 deficiency—
the twin sibling diagnosed aged 22 days in the course of 
selective diagnostics of patient N3 and patient S4 diagnosed 
aged 10 weeks. As discussed above it seems likely that in 
both children, mild vitamin  B12 deficiency has developed 
in the first weeks of life. Comparing MMA results in our 
patients with a publication by Schroder and colleagues pre-
senting a reference interval for MMA in DBS in full-term 
infants of 0.45–1.33 µmol/L [46] 9 of 11 children with vita-
min  B12 deficiency from our study had MMA results in their 
first NBS sample above this reference range, the upper limit 
equalling the 97.5th percentile. This comparison is, however, 
limited because of the use of different methods [23, 46]. The 
97.5th percentile for MMA using our method is currently 
1.85 µmol/L (and was 1.66 µmol/L with the reagents used by 
the time patient samples N1-N4 and S3 were analysed). With 
regard to these cut-offs, 8 of 11 children with vitamin  B12 
deficiency showed elevated MMA in their first NBS sample.
From our current stage of evaluation we conclude that 
the proposed second-tier strategy in our study is very effec-
tive for identification of maternal vitamin  B12 deficiency 
for moderate and severe cases, but that mild vitamin  B12 
deficiency might not always be picked up. The results of 
the first 13 months of this study are presented, as awareness 
of these findings is important from a public health point of 
view. Provided proof for the feasibility of the methods used 
in a population-based screening programme in more than 
68,000 samples, and of the benefit for patients identified 
will hopefully lead to timely inclusion of these additional 
disorders into the NBS panel for Germany as part of regular 
health insurance.
In conclusion,  within the first 13 months, the strategies 
currently used in our study “Newborn Screening 2020” 
identified additional 12 children with metabolic disorders 
or maternal vitamin  B12 deficiency in a cohort of 68,418 
study participants, while the recall rate was only marginally 
increased by 0.1%. Except one child, all patients were identi-
fied presymtomatically. Maternal vitamin  B12 deficiency was 
the most frequent finding. This project will allow to evaluate 
the false-positive rate and positive predictive value of the 
proposed second-tier strategy over the following years. It can 
be expected that numerous children will benefit from screen-
ing for the additional target disorders in the further course of 
the study and even more in case of a future extension of the 
NBS panels in Germany and other countries.
Author contributions GG contributed to study design, collection, 
evaluation and interpretation of data, drafting and writing of the man-
uscript. JFH contributed to contribution and interpretation of data, 
and revision of the manuscript. PF contributed to study design, data 
acquisition and management, and revision of the manuscript. PM and 
GK contributed to development of the laboratory methods, contribu-
tion and interpretation of data, and revision of the manuscript. JGO  
480 World Journal of Pediatrics (2018) 14:470–481
1 3
contributed to study design, development of the laboratory methods, 
and revision of the manuscript. GFH contributed to study design, inter-
pretation of data, and revision of the manuscript. All authors approved 
the final version of the manuscript.
Funding This study is generously supported by the Dietmar Hopp 
Foundation, St. Leon-Rot, Germany. The authors confirm independ-
ence from the sponsor; the content of the article has not been influenced 
by the sponsor.
Compliance with ethical standards 
Ethical approval The study “Newborn Screening 2020” as well as ret-
rospective evaluation of NBS results of patients diagnosed by selective 
screening has been approved by the Ethics Committee of the Univer-
sity Hospital Heidelberg (no. S-533/2015). Written informed consent 
was obtained from parents before participation of children in the study 
“Newborn Screening 2020”.
Conflict of interest GG received a lecture fee from MetaX, Friedberg; 
JFH, PF, GK, PM, JGO, and GFH report no disclosures.
References
 1. Gramer G, Hauck F, Lobitz S, Sommerburg O, Speckmann 
C, Hoffmann GF. Newborn screening 2020; Perspectives 
for early disease recognition. Monatsschr Kinderheilkd. 
2017;165:216–25.
 2. Huemer M, Kozich V, Rinaldo P, Baumgartner MR, Merinero 
B, Pasquini E, et al. Newborn screening for homocystinurias and 
methylation disorders: systematic review and proposed guidelines. 
J Inherit Metab Dis. 2015;38:1007–19.
 3. Wong D, Tortorelli S, Bishop L, Sellars EA, Schimmenti LA, 
Gallant N, et al. Outcomes of four patients with homocysteine 
remethylation disorders detected by newborn screening. Genet 
Med. 2016;18:162–7.
 4. El Bashir H, Dekair L, Mahmoud Y, Ben-Omran T. Neurodevel-
opmental and cognitive outcomes of classical homocystinuria: 
experience from qatar. JIMD Rep. 2015;21:89–95.
 5. Whitehead VM. Acquired and inherited disorders of cobalamin 
and folate in children. Br J Haematol. 2006;134:125–36.
 6. Singh G, Le D, Schnabl K, Leaker MT, Steele M, Sparkes RL. 
Vitamin B12 deficiency in infancy: the case for screening. Pediatr 
Blood Cancer. 2016;63:740–2.
 7. Jain R, Singh A, Mittal M, Talukdar B. Vitamin B12 deficiency in 
children: a treatable cause of neurodevelopmental delay. J Child 
Neurol. 2015;30:641–3.
 8. Advisory Committee on Heritable Disorders in Newborns and 
Children. Health Resources and Services Administration. Recom-
mended Uniform Screening Panel. https ://www.hrsa.gov/advis 
ory-commi ttees /herit able-disor ders/rusp/index .html. Accessed 
13 Mar 2018.
 9. American College of Medical Genetics Newborn Screening Expert 
Group. Newborn screening: toward a uniform screening panel and 
system–executive summary. Pediatrics. 2006;117:S296–307.
 10. Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall 
D, Chapman KA, et al. Proposed guidelines for the diagnosis and 
management of methylmalonic and propionic acidemia. Orphanet 
J Rare Dis. 2014;9:130.
 11. Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, 
Borrajo GJ, et al. Current status of newborn screening worldwide: 
2015. Semin Perinatol. 2015;39:171–87.
 12. la Marca G, Malvagia S, Pasquini E, Innocenti M, Donati MA, 
Zammarchi E. Rapid 2nd-tier test for measurement of 3-OH-
propionic and methylmalonic acids on dried blood spots: reduc-
ing the false-positive rate for propionylcarnitine during expanded 
newborn screening by liquid chromatography-tandem mass spec-
trometry. Clin Chem. 2007;53:1364–9.
 13. Chace DH, DiPerna JC, Kalas TA, Johnson RW, Naylor EW. 
Rapid diagnosis of methylmalonic and propionic acidemias: quan-
titative tandem mass spectrometric analysis of propionylcarnitine 
in filter-paper blood specimens obtained from newborns. Clin 
Chem. 2001;47:2040–4.
 14. Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduc-
tion of the false-positive rate in newborn screening by implemen-
tation of MS/MS-based second-tier tests: the Mayo Clinic experi-
ence (2004-2007). J Inherit Metab Dis. 2007;30:585–92.
 15. Turgeon CT, Magera MJ, Cuthbert CD, Loken PR, Gavrilov DK, 
Tortorelli S, et al. Determination of total homocysteine, meth-
ylmalonic acid, and 2-methylcitric acid in dried blood spots by 
tandem mass spectrometry. Clin Chem. 2010;56:1686–95.
 16. Gramer G, Abdoh G, Ben-Omran T, Shahbeck N, Ali R, Mahmoud 
L, et al. Newborn screening for remethylation disorders and vita-
min B12 deficiency-evaluation of new strategies in cohorts from 
Qatar and Germany. World J Pediatr. 2017;13:136–43.
 17. Okun JG, Gan-Schreier H, Ben-Omran T, Schmidt KV, Fang-
Hoffmann J, Gramer G, et al. Newborn screening for vitamin B6 
non-responsive classical homocystinuria—systematical evaluation 
of a two-tier strategy. JIMD Rep. 2017;32:87–94.
 18. Gramer G, Okun JG, Hoffmann GF. Pilot study for evaluation of 
21 additional metabolic disorders for the German newborn screen-
ing panel. J Inherit Metab Dis. 2016;39(Suppl 1):75.
 19. German Society for Newborn Screening. Screening reports. http://
www.scree ning-dgns.de/repor ts.php. Accessed 6 Mar 2017.
 20. Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayate-
pek E, Hoffmann GF. Expanded newborn screening for inborn 
errors of metabolism by electrospray ionization-tandem mass 
spectrometry: results, outcome, and implications. Pediatrics. 
2003;111:1399–406.
 21. Röschinger W, Sonnenschein S, Schuhmann E, Nennstiel-Ratzel 
U, Roscher AA, Olgemöller B. New target diseases in newborn 
screening. Recommendations derived from a pilot study. Monatss-
chr Kinderheilkd. 2015;2:142–9.
 22. Gan-Schreier H, Kebbewar M, Fang-Hoffmann J, Wilrich J, 
Abdoh G, Ben-Omran T, et al. Newborn population screening for 
classic homocystinuria by determination of total homocysteine 
from Guthrie cards. J Pediatr. 2010;156:427–32.
 23. Monostori P, Klinke G, Richter S, Baráth Á, Fingerhut R, Baum-
gartner MR, et al. Simultaneous determination of 3-hydroxypro-
pionic acid, methylmalonic acid and methylcitric acid in dried 
blood spots: second-tier LC-MS/MS assay for newborn screening 
of propionic acidemia, methylmalonic acidemias and combined 
remethylation disorders. PLoS One. 2017;12:e0184897.
 24. Sahm F, Capper D, Pusch S, Balss J, Koch A, Langhans CD, et al. 
Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embed-
ded glioma specimens by gas chromatography/mass spectrometry. 
Brain Pathol. 2012;22:26–31.
 25. Scolamiero E, Villani GR, Ingenito L, Pecce R, Albano L, 
Caterino M, et al. Maternal vitamin B12 deficiency detected in 
expanded newborn screening. Clin Biochem. 2014;47:312–7.
 26. Honzik T, Adamovicova M, Smolka V, Magner M, Hruba E, 
Zeman J. Clinical presentation and metabolic consequences in 40 
breastfed infants with nutritional vitamin B12 deficiency—what 
have we learned? Eur J Paediatr Neurol. 2010;14:488–95.
 27. Hinton CF, Ojodu JA, Fernhoff PM, Rasmussen SA, Scanlon 
KS, Hannon WH. Maternal and neonatal vitamin B12 deficiency 
detected through expanded newborn screening—United States, 
2003–2007. J Pediatr. 2010;157:162–3.
481World Journal of Pediatrics (2018) 14:470–481 
1 3
 28. Richter M, Beoing H, Grünewald-Funk D, Heseker H, Kroke 
A, Leschik-Bonnet E, et al. Vegan Diet–Position of the German 
Nutrition Society (DGE). Ernährungs Umschau. 2016;63:92–102.
 29. Reinson K, Künnapas K, Kriisa A, Vals M, Muru K, Õunap K. 
Very high incidence of low vitamin B12 in estonian newborns. 
Meeting Report ISNS 9th International Symposium, 11–14 Sep 
2016, The Hague, The Netherlands.
 30. Obeid R, Murphy M, Solé-Navais P, Yajnik C. Cobalamin status 
from pregnancy to early childhood: lessons from global experi-
ence. Adv Nutr. 2017;8:971–9.
 31. Sukumar N, Rafnsson SB, Kandala NB, Bhopal R, Yajnik CS, 
Saravanan P. Prevalence of vitamin B-12 insufficiency during 
pregnancy and its effect on offspring birth weight: a systematic 
review and meta-analysis. Am J Clin Nutr. 2016;103:1232–51.
 32. Murphy MM, Molloy AM, Ueland PM, Fernandez-Ballart JD, 
Schneede J, Arija V, et al. Longitudinal study of the effect of preg-
nancy on maternal and fetal cobalamin status in healthy women 
and their offspring. J Nutr. 2007;137:1863–7.
 33. Murphy MM, Scott JM, Arija V, Molloy AM, Fernandez-Ballart 
JD. Maternal homocysteine before conception and throughout 
pregnancy predicts fetal homocysteine and birth weight. Clin 
Chem. 2004;50:1406–12.
 34. Ray JG, Goodman J, O’Mahoney PR, Mamdani MM, Jiang 
D. High rate of maternal vitamin B12 deficiency nearly a 
decade after Canadian folic acid flour fortification. QJM. 
2008;101:475–7.
 35. Jeruszka-Bielak M, Isman C, Schroder TH, Li W, Green TJ, 
Lamers Y. South Asian ethnicity is related to the highest risk of 
vitamin B12 deficiency in pregnant Canadian women. Nutrients 
2017;9:317.
 36. Schroder TH, Sinclair G, Mattman A, Jung B, Barr SI, Vallance 
HD, et al. Pregnant women of South Asian ethnicity in Canada 
have substantially lower vitamin B12 status compared with preg-
nant women of European ethnicity. Br J Nutr. 2017;118:454–62.
 37. Finkelstein JL, Kurpad AV, Thomas T, Srinivasan K, Duggan C. 
Vitamin  B12 status in pregnant women and their infants in South 
India. Eur J Clin Nutr. 2017;71:1046–53.
 38. Sukumar N, Venkataraman H, Wilson S, Goljan I, Selvamoni 
S, Patel V, et al. Vitamin B12 status among pregnant women in 
the UK and its association with obesity and gestational diabetes. 
Nutrients. 2016;8:768.
 39. Wiley V, Carpenter K, Wilcken B. Newborn screening with tan-
dem mass spectrometry: 12 months’ experience in NSW Australia. 
Acta Paediatr Suppl. 1999;88:48–51.
 40. Lim JS, Tan ES, John CM, Poh S, Yeo SJ, Ang JS, et al. Inborn 
error of metabolism (IEM) screening in Singapore by electro-
spray ionization-tandem mass spectrometry (ESI/MS/MS): an 
8 year journey from pilot to current program. Mol Genet Metab. 
2014;113:53–61.
 41. Sarafoglou K, Rodgers J, Hietala A, Matern D, Bentler K. 
Expanded newborn screening for detection of vitamin B12 defi-
ciency. JAMA. 2011;305:1198–200.
 42. Huemer M, Scholl-Burgi S, Hadaya K, Kern I, Beer R, Seppi K, 
et al. Three new cases of late-onset cblC defect and review of the 
literature illustrating when to consider inborn errors of metabo-
lism beyond infancy. Orphanet J Rare Dis. 2014;9:161.
 43. Weisfeld-Adams JD, Bender HA, Miley-Akerstedt A, Frempong T, 
Schrager NL, Patel K, et al. Neurologic and neurodevelopmental 
phenotypes in young children with early-treated combined meth-
ylmalonic acidemia and homocystinuria, cobalamin C type. Mol 
Genet Metab. 2013;110:241–7.
 44. Fischer S, Huemer M, Baumgartner M, Deodato F, Ballhausen 
D, Boneh A, et  al. Clinical presentation and outcome in a 
series of 88 patients with the cblC defect. J Inherit Metab Dis. 
2014;37:831–40.
 45. Weisfeld-Adams JD, Morrissey MA, Kirmse BM, Salveson 
BR, Wasserstein MP, McGuire PJ, et al. Newborn screening 
and early biochemical follow-up in combined methylmalonic 
aciduria and homocystinuria, cblC type, and utility of methio-
nine as a secondary screening analyte. Mol Genet Metab. 
2010;99:116–23.
 46. Schroder TH, Mattman A, Sinclair G, Vallance HD, Lamers 
Y. Reference interval of methylmalonic acid concentrations 
in dried blood spots of healthy, term newborns to facilitate 
neonatal screening of vitamin B12 deficiency. Clin Biochem. 
2016;49:973–8.
 47. Schroder TH, Quay TA, Lamers Y. Methylmalonic acid quantified 
in dried blood spots provides a precise, valid, and stable meas-
ure of functional vitamin B-12 status in healthy women. J Nutr. 
2014;144:1658–63.
 48. Chanarin I, Metz J. Diagnosis of cobalamin deficiency: the old 
and the new. Br J Haematol. 1997;97:695–700.
